Industry

Offering was led by an initial investment from a premier healthcare-dedicated investor alongside multiple large existing shareholders Company’s total cash position expected to be approximately $70 million following closing VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced … [Read more…]

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by … [Read more…]

MINNEAPOLIS–(BUSINESS WIRE)–#cyclopure–Kurita America Inc., a global leader in water treatment solutions, and Cyclopure, an innovator in advanced adsorbent technologies, today announced their expanding partnership to deliver the most advanced and sustainable solution for removing per- and polyfluoroalkyl substances (PFAS) from water with a completely regenerable material. With Cyclopure’s patented DEXSORB® technology and Kurita’s expertise in … [Read more…]

CHICAGO–(BUSINESS WIRE)–Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, is providing estimated financial performance for the second quarter of 2025 compared to the prior year, details about its recent financing activities, and reaffirmation of its outlook for the 2025 fiscal year. On Tuesday, September 2, longtime healthcare IT industry veteran Donald … [Read more…]

Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer’s ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next … [Read more…]

HAYWARD, Calif.–(BUSINESS WIRE)–#BGRT—RefleXion Medical, an external‑beam theranostic oncology company, today announced first results from the PREMIER Registry (NCT05406167) evaluating its SCINTIX® biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported … [Read more…]

BELMONT, Mich.–(BUSINESS WIRE)–#avasure—AvaSure, the market leader in acute virtual care, proudly announced the recipients of the 9th annual 2025 AvaPrize Awards during the AvaSure Symposium in Charlotte, NC. The AvaPrize honors healthcare organizations and individuals who demonstrate exceptional leadership, innovation, and impact in advancing patient safety and virtual care delivery. “Each of these winners represents … [Read more…]

Results showed the benefits of early initiation of WINREVAIR within the first year after PAH diagnosis HYPERION results were presented today at ERS 2025 and simultaneously published in the New England Journal of Medicine RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase … [Read more…]

Uses radio waves to monitor and track data, will help enhance health and general well-being TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a new type of contactless body data sensor that can detect minute variations in heart rates, respiration, and other vital body indicators with high precision. It will enable … [Read more…]

ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today responded to a now retracted LinkedIn post referencing voclosporin by an FDA official. Aurinia stands behind the favorable benefit/risk profile of LUPKYNIS® (voclosporin). LUPKYNIS received full approval from the FDA in January 2021 based on a large, randomized 52-week clinical study known as AURORA … [Read more…]